Neonatal Screening for Congenital Adrenal Hyperplasia in Denmark: 10 Years of Experience
暂无分享,去创建一个
D. Hougaard | K. Main | M. Bækvad-Hansen | C. Gravholt | M. Duno | L. Melgaard | A. Cohen | D. Hansen | K. Skogstrand | A. Berglund | Marie Lind-Holst | Marie Bækvad-Hansen | Agnethe Berglund
[1] P. Hofman,et al. Birthweight or Gestational Age Adjusted Second Tier LCMSMS Cut-offs Improve Newborn Screening for CAH in New Zealand. , 2021, The Journal of clinical endocrinology and metabolism.
[2] I. Bird,et al. Newborn Screening for Congenital Adrenal Hyperplasia: Review of Factors Affecting Screening Accuracy , 2020, International journal of neonatal screening.
[3] V. Wiley,et al. Evaluation of a Two-Tier Screening Pathway for Congenital Adrenal Hyperplasia in the New South Wales Newborn Screening Programme , 2020, International journal of neonatal screening.
[4] H. Vallance,et al. Clinical Impact and Cost Efficacy of Newborn Screening for Congenital Adrenal Hyperplasia. , 2020, The Journal of pediatrics.
[5] P. Hofman,et al. Measurement of 17-Hydroxyprogesterone by LCMSMS Improves Newborn Screening for CAH Due to 21-Hydroxylase Deficiency in New Zealand , 2020, International journal of neonatal screening.
[6] D. Hougaard,et al. Danish expanded newborn screening is a successful preventive public health programme. , 2020, Danish medical journal.
[7] Sichi Liu,et al. The adjustment of 17-hydroxyprogesterone cut-off values for congenital adrenal hyperplasia neonatal screening by GSP according to gestational age and age at sampling , 2019, Journal of pediatric endocrinology & metabolism : JPEM.
[8] S. Almashanu,et al. Combined Gestational Age- and Birth Weight-Adjusted Cutoffs for Newborn Screening of Congenital Adrenal Hyperplasia. , 2019, The Journal of clinical endocrinology and metabolism.
[9] M. Finken,et al. Evaluation of the Dutch neonatal screening for congenital adrenal hyperplasia , 2019, Archives of Disease in Childhood.
[10] Norma P. Tavakoli,et al. Newborn screening for congenital adrenal hyperplasia in New York State , 2016, Molecular genetics and metabolism reports.
[11] Yannan Jiang,et al. Newborn screening for congenital adrenal hyperplasia in New Zealand, 1994-2013. , 2015, The Journal of clinical endocrinology and metabolism.
[12] A. Nordenström,et al. Nationwide neonatal screening for congenital adrenal hyperplasia in sweden: a 26-year longitudinal prospective population-based study. , 2014, JAMA pediatrics.
[13] W. Thomas,et al. Comparison of newborn screening protocols for congenital adrenal hyperplasia in preterm infants. , 2014, The Journal of pediatrics.
[14] P. Clayton,et al. No evidence of an increase in early infant mortality from congenital adrenal hyperplasia in the absence of screening , 2013, Archives of Disease in Childhood.
[15] H. Falhammar,et al. One hundred years of congenital adrenal hyperplasia in Sweden: a retrospective, population-based cohort study. , 2013, The lancet. Diabetes & endocrinology.
[16] Flemming Skovby,et al. Biochemical screening of 504,049 newborns in Denmark, the Faroe Islands and Greenland--experience and development of a routine program for expanded newborn screening. , 2012, Molecular genetics and metabolism.
[17] W. Thomas,et al. Comparison of One-Tier and Two-Tier Newborn Screening Metrics for Congenital Adrenal Hyperplasia , 2012, Pediatrics.
[18] I. Silva,et al. Neonatal screening for congenital adrenal hyperplasia. , 2012, Revista da Associacao Medica Brasileira.
[19] J. Coste,et al. Efficiency of neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children born in mainland France between 1996 and 2003. , 2012, Archives of pediatrics & adolescent medicine.
[20] P. Hindmarsh,et al. Incidence and clinical features of congenital adrenal hyperplasia in Great Britain , 2012, Archives of Disease in Childhood.
[21] V. Montori,et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. , 2010, The Journal of clinical endocrinology and metabolism.
[22] M. Morris,et al. Serum steroid profiling for congenital adrenal hyperplasia using liquid chromatography-tandem mass spectrometry. , 2010, Clinica chimica acta; international journal of clinical chemistry.
[23] E. Elliott,et al. Two‐year pilot study of newborn screening for congenital adrenal hyperlasia in New South Wales compared with nationwide case surveillance in Australia , 2008, Journal of paediatrics and child health.
[24] M. Peter,et al. Fast and direct quantification of adrenal steroids by tandem mass spectrometry in serum and dried blood spots. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[25] J. Wit,et al. Cutoff levels of 17-alpha-hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight. , 2005, The Journal of clinical endocrinology and metabolism.
[26] B. Casetta,et al. Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. , 2004, Clinical chemistry.
[27] E. Schoenle,et al. High reliability of neonatal screening for congenital adrenal hyperplasia in Switzerland. , 2002, The Journal of clinical endocrinology and metabolism.
[28] S. Berenbaum,et al. Results of Screening 1.9 Million Texas Newborns for 21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia , 1998, Pediatrics.
[29] A. Nordenström,et al. Benefits of Neonatal Screening for Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency) in Sweden , 1998, Pediatrics.
[30] A. Larsson,et al. Congenital Adrenal Hyperplasia in Sweden 1969‐1986 Prevalence, Symptoms and Age at Diagnosis , 1990, Acta paediatrica Scandinavica.
[31] M. New,et al. Congenital adrenal hyperplasia. , 1988, Biochemical Society transactions.